Stockreport

Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight [Yahoo! Finance]

NewAmsterdam Pharma Company N.V. - Ordinary Shares  (NAMS) 
PDF attributed to the launch of upcoming therapies such as Olpasiran (AMG 890) (Amgen/Arrowhead Pharmaceuticals), Obicetrapib (TA-8995) (Newamsterdam Pharma/Menarini), Apabe [Read more]